FDA Issues 30 Warning Letters to Telehealth Firms Over Compounded GLP-1 Marketing Claims
On March 3, 2026, the U.S. Food and Drug Administration (FDA) announced that it has issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products marketed on their websites.
The enforcement action marks the second wave of warning letters since the FDA launched its September 2025 initiative targeting misleading direct-to-consumer pharmaceutical advertising, particularly in digital and telehealth channels.
According to the agency, the primary violations involved implying that compounded GLP-1 products are the same as FDA-approved versions, suggesting equivalence to approved branded drugs, obscuring product sourcing, and advertising compounded products under telehealth company brand names in ways that imply the telehealth firm itself is the compounder.
FDA Commissioner Marty Makary, M.D., M.P.H., emphasized that while compounding can serve legitimate purposes like addressing drug shortages or meeting individualized patient needs, compounders must not use compounding as a pathway to circumvent FDA approval requirements.
Regulatory Context: Compounded Drugs vs. FDA-Approved Products
The FDA reiterated several key distinctions. Compounded drugs are not FDA-approved, the FDA does not review compounded products for safety, effectiveness, or quality prior to marketing, and compounded drugs are not equivalent to FDA-approved generics.
These distinctions are central to the agency’s concern. Marketing language that implies “sameness” with approved GLP-1 products risks misleading patients and blurring regulatory boundaries.
Escalating Enforcement Trend
Over the past six months, the FDA reports issuing thousands of letters to pharmaceutical and telehealth companies regarding misleading promotional practices; more than were issued during the entire previous decade.
This signals a clear shift toward more aggressive oversight of digital pharmaceutical marketing, particularly in high-demand therapeutic areas such as GLP-1 medications used for diabetes and weight management.
MDP Analysis: What This Means for Industry
This action highlights several important compliance considerations:
Telehealth Is Not a Regulatory Shortcut
Branding compounded products under telehealth company names without clear qualification raises sourcing and labeling concerns.
Sameness Claims Are High Risk
Even implied equivalence to FDA-approved GLP-1 products can trigger enforcement action.
Digital Advertising Is Under Active Surveillance
FDA’s current posture indicates ongoing monitoring of online pharmaceutical marketing practices.
Compounding Must Remain Within Statutory Boundaries
Sections 503A and 503B of the FD&C Act establish clear guardrails for compounding. Promotional overreach can jeopardize those protections.
Compliance Takeaway
Telehealth platforms, pharmacies, and outsourcing facilities must review all promotional materials for implied equivalence claims, clearly disclose compounded status where applicable, avoid brand positioning that obscures the actual compounder, and ensure marketing teams understand the regulatory distinctions between approved drugs, generics, and compounded products.
The FDA’s message is clear. Compounding is permitted within defined regulatory frameworks, but it cannot function as an alternative approval pathway.
Links
Read the FDA’s announcement here.
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
Eugia Vancomycin Recall: Glass Particle Contamination
FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...
FDA Requires New GLP-1 Drug Warning for Vision Loss Risk
Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...
When Political Priorities and FDA Science Collide
HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...
What to Know about FDA’s Revised Peptide Guidance
What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...
The Regulatory Dilemma of Experimental Peptides
As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...